Skip to main content

Hematopoietic Cell Transplantation clinical trials at UC Davis

6 research studies open to eligible people

Showing trials for
  • A Study of Experimental Tabelecleucel in Subjects with Epstein-Barr Virus-associated Diseases (Mono)

    open to all eligible people

    The purpose of this study is to assess the efficacy and safety of tabelecleucel in participants with Epstein-Barr virus (EBV) associated diseases.

    Sacramento, California and other locations

  • A Study of RV521 in the Treatment of Adult Subjects With an Upper Respiratory Tract Infection

    open to eligible people ages 18-75

    RV521 is to being developed to treat RSV infection and disease in susceptible individuals at high risk for complications. This is an international, multicenter, placebo-controlled study. Eligible subjects are adults with a documented symptomatic RSV infection who have undergone HCT transplantation and are moderately to severely immunocompromised. Qualified subjects will be randomized in a 1:1 ratio to receive RV521 or placebo, twice daily for 10 days.

    Sacramento, California and other locations

  • A Study of the Safety and Effectiveness of Experimental BIVV003 for Stem Cell Transplant for Severe Sickle Cell Disease

    open to eligible people ages 18-40

    This is an open label, multicenter, Phase 1/2 study in approximately eight adults with severe Sickle Cell Disease (SCD). The study will evaluate the safety, tolerability, and efficacy of autologous hematopoietic stem cell transplantation using BIVV003.

    Sacramento, California and other locations

  • Experimental Letermovir (LET) to Prevent Cytomegalovirus (CMV) Infection After Stem Cell Transplant

    open to eligible people ages 18 years and up

    The purpose of this study is to evaluate the safety and efficacy of letermovir (LET) versus placebo when extended from 100 days to 200 days post-transplant in cytomegalovirus (CMV) seropositive participants who received an allogenic hematopoietic stem cell transplant (HSCT). It is hypothesized that LET is superior to placebo in the prevention of clinically-significant CMV infection when LET prophylaxis is extended from 100 to 200 days.

    Sacramento, California and other locations

  • Experimental Vedolizumab for Acute Graft Versus Host Disease (aGVHD) in Stem Cell Transplants

    open to eligible people ages 12 years and up

    The purpose of this study is to evaluate the efficacy of vedolizumab when added to background aGvHD prophylaxis regimen compared to placebo and background aGvHD prophylaxis regimen on intestinal aGvHD-free survival by Day +180 in participants who receive allo-HSCT as treatment for a hematologic malignancy or myeloproliferative disorder.

    Los Angeles, California and other locations

  • Long-Term Follow-Up of Patients Who Have Participated in Children's Oncology Group Studies

    open to all eligible people

    This clinical trial keeps track of and collects follow-up information from patients who are currently enrolled on or have participated in a Children's Oncology Group study. Developing a way to keep track of patients who have participated in Children's Oncology Group studies may allow doctors learn more about the long-term effects of cancer treatment and help them reduce problems related to treatment and improve patient quality of life.

    Sacramento, California and other locations

Our lead scientists for Hematopoietic Cell Transplantation research studies include .

Last updated: